European Medicines Agency Pre-Authorisation Procedural Advice

# Executive Summary This whitepaper provides essential procedural advice for users of the European Medicines Agency's centralised procedure, focusing on: - The expiration of the Irish language derogation affecting marketing authorisation communications. - Mandatory registration of new sites and organisations for centrally-authorised medicinal products. - The significance of pre-submission meetings for regulatory compliance and application validation. - Updates on eligibility requests and application processes for various medicinal products. - Emphasis on compliance with EU legislation for marketing authorisation applications.